RT Journal Article
T1 SEOM clinical guideline for the management of malignant melanoma (2017).
A1 Berrocal, A
A1 Arance, A
A1 Castellon, V E
A1 de la Cruz, L
A1 Espinosa, E
A1 Cao, M G
A1 Larriba, J L G
A1 Márquez-Rodas, I
A1 Soria, A
A1 Algarra, S M
K1 Adjuvant
K1 B-RAF
K1 Immunotherapy
K1 Melanoma
K1 Metastatic
AB All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
YR 2017
FD 2017-11-07
LK http://hdl.handle.net/10668/11780
UL http://hdl.handle.net/10668/11780
LA en
DS RISalud
RD Apr 7, 2025